Viking Therapeutics: A Major Player in the Weight Loss Arena
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy VKTX?
Source: Marketbeat
Current Market Dynamics: The pharmaceutical industry is experiencing a significant shift with a demand for new players to disrupt the dominance of established companies like Novo Nordisk and Eli Lilly in obesity treatments, creating opportunities for agile competitors like Viking Therapeutics.
Viking's Competitive Edge: Viking Therapeutics has emerged as a leading challenger in the obesity treatment market, with its primary asset, VK2735, showing promising results in clinical trials, including significant weight loss outcomes.
Strategic Developments: Viking is strategically positioning itself for potential acquisition while simultaneously building its infrastructure for independent operations, highlighted by recent key appointments and partnerships to enhance its manufacturing capabilities.
Investment Outlook: Despite current losses and skepticism in the market, Viking's strong cash reserves and advanced clinical data present a compelling investment opportunity, with analysts suggesting significant upside potential if the company successfully executes its roadmap.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.960
Low
70.00
Averages
97.00
High
125.00
Current: 32.960
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pharma Acquisition Surge Fuels Weight Loss Drug Market
- Acquisition Trend: Pharmaceutical companies are increasingly turning to acquisitions as a primary route to enter advanced weight-loss therapy pipelines, with heightened expectations for Viking Therapeutics and Structure Therapeutics, indicating strong industry interest in the obesity drug market.
- VK2735 Gains Attention: Viking's dual-agonist obesity therapy VK2735 is advancing through Phase 3 trials, and investor optimism is reflected in a more than 2% rise in stock price during extended trading, showcasing market confidence in potential acquisitions.
- Market Dynamics Shift: With Eli Lilly and other pharma companies actively pursuing smaller pipeline acquisitions, interest in obesity drugs has surged, exemplified by Eli Lilly's recent acquisition of Centessa Pharmaceuticals for up to $7.8 billion, highlighting a preference for smaller deals in the sector.
- VKTX Retail Sentiment Shift: Retail sentiment for VKTX has shifted from 'bullish' to 'neutral' in the past day amid a 1,155% surge in message volume, reflecting investor focus and uncertainty about its future performance, with the stock rising 38% over the past year.
See More
Viking Therapeutics Faces Challenges in Weight Loss Market
- Clinical Trial Progress: Viking Therapeutics' leading candidate VK2735 is undergoing pivotal 78-week phase 3 studies, with the second study recently completing enrollment; strong results could establish a solid foundation for the company in the competitive weight-loss market.
- Significant Market Potential: Analysts predict VK2735 could generate peak sales of $14.4 billion in the U.S. and $7.2 billion in Europe, totaling $21.6 billion, highlighting the drug's market potential as the weight-loss sector is projected to exceed $100 billion in the next decade.
- Increasing Competitive Pressure: While VK2735 aims to match the efficacy of Eli Lilly's Zepbound, Viking Therapeutics must demonstrate exceptional results in clinical trials to secure its position in the weight-loss drug market as competition intensifies.
- Investment Risk Advisory: Viking Therapeutics faces clinical, regulatory, competitive, and funding challenges, and while its stock may soar over the next decade, the risk of bankruptcy remains, necessitating cautious consideration from investors.
See More
Viking Therapeutics Faces Major Clinical Challenges Ahead
- Clinical Trial Progress: Viking Therapeutics' leading candidate VK2735 is undergoing two 78-week phase 3 studies, with the second recently completing enrollment; strong results could significantly enhance the company's competitive position in the rapidly growing weight-loss market.
- Massive Market Potential: Analysts predict VK2735 could generate peak sales of $14.4 billion in the U.S. and $7.2 billion in Europe, totaling $21.6 billion, and if it matches Eli Lilly's Zepbound, Viking's stock price could soar.
- Oral Drug Advantage: Viking's oral VK2735 completed phase 2 studies last year, and if it performs well in pivotal trials, it will further solidify its market position, particularly in attracting patients hesitant about injectable medications.
- Risks and Challenges: Despite the optimistic outlook, Viking Therapeutics faces clinical and regulatory risks, and increasing competition may hinder its commercial success, necessitating cautious evaluation of potential risks by investors.
See More
Wegovy Pill Shows Superior Weight Loss Over Foundayo
- Weight Loss Efficacy: The Wegovy pill demonstrated significantly greater mean weight loss of 16.6% compared to Eli Lilly's Foundayo, which showed only 12.4%, indicating Wegovy's competitive edge in the weight-loss drug market.
- Patient Preference Insights: An analysis by Novo revealed that 84% of patients preferred the drug profile of Wegovy, highlighting strong patient recognition of its lifestyle compatibility, which provides robust support for Novo's market promotion efforts.
- Market Competition Dynamics: The launch of the Wegovy pill is seen as the beginning of a new era in weight-loss medications; however, analysts note that the rapid increase in prescriptions may slow down as Foundayo approaches its market entry, potentially impacting Wegovy's market share.
- Side Effect Comparison: Recent studies indicate that Wegovy outperforms Foundayo in terms of discontinuation rates, with the latter associated with about 14 times higher odds of stopping treatment due to side effects, providing Wegovy with a crucial differentiation advantage in the increasingly competitive anti-obesity drug market.
See More
Investment Opportunities in the Healthcare Sector
- Viking Therapeutics Outlook: Viking Therapeutics has completed enrollment for its pivotal phase 3 trial of VK2735, with results expected next year, and analysts believe its stock could rise by over 60% in the coming year, with some predicting a price target exceeding $107 per share due to its leading position in obesity drug development.
- HCA Healthcare Growth Potential: HCA Healthcare operates 186 hospitals and approximately 2,400 outpatient facilities in the U.S., with same-facility admissions rising 2.4% year-over-year in Q4 2025, contributing to nearly 7% revenue growth, and management anticipates a 6% increase in annual revenue this year, driven by an aging population.
- Aging Population Drives Medical Demand: The 2020 census reported 55.8 million people aged 65 and older, accounting for 17% of the population, with projections estimating this will rise to 71.6 million by 2030, comprising 20.7% of the population, thereby increasing demand for HCA's healthcare services and strengthening its market position.
- AI Technology Enhances Operational Efficiency: HCA is leveraging its Timpani platform to improve nurse staffing through artificial intelligence, addressing bottlenecks in the U.S. healthcare system, and this forward-looking management strategy is expected to enhance service quality and operational efficiency, thereby increasing its long-term investment appeal.
See More
Investment Opportunities in Biotech and Healthcare Systems
- Biotech Potential: Viking Therapeutics has completed enrollment in a crucial phase 3 trial for its VK2735 drug, with results expected next year; analysts predict a stock price target between $107 and $125, indicating strong market potential if approved.
- Healthcare System Growth: HCA Healthcare operates 186 hospitals and 2,400 outpatient facilities in the U.S., with same-facility admissions rising 2.4% year-over-year in Q4 2025, boosting overall revenue by nearly 7% to $19.5 billion, showcasing its market advantage amid an aging population.
- Demographic Trends Impact: The 2020 census reported 55.8 million people aged 65 and older, making up 17% of the population, projected to rise to 71.6 million by 2030, comprising 20.7%, which will further drive demand for HCA's healthcare services, creating long-term growth momentum.
- AI Technology Application: HCA is leveraging its Timpani platform to improve nurse staffing through artificial intelligence, addressing bottlenecks in the U.S. healthcare system; while some market analysts are cautious about a 60% stock price increase, its long-term investment value remains significant.
See More
Pharma Acquisition Surge Fuels Weight Loss Drug Market
- Acquisition Trend: Pharmaceutical companies are increasingly turning to acquisitions as a primary route to enter advanced weight-loss therapy pipelines, with heightened expectations for Viking Therapeutics and Structure Therapeutics, indicating strong industry interest in the obesity drug market.
- VK2735 Gains Attention: Viking's dual-agonist obesity therapy VK2735 is advancing through Phase 3 trials, and investor optimism is reflected in a more than 2% rise in stock price during extended trading, showcasing market confidence in potential acquisitions.
- Market Dynamics Shift: With Eli Lilly and other pharma companies actively pursuing smaller pipeline acquisitions, interest in obesity drugs has surged, exemplified by Eli Lilly's recent acquisition of Centessa Pharmaceuticals for up to $7.8 billion, highlighting a preference for smaller deals in the sector.
- VKTX Retail Sentiment Shift: Retail sentiment for VKTX has shifted from 'bullish' to 'neutral' in the past day amid a 1,155% surge in message volume, reflecting investor focus and uncertainty about its future performance, with the stock rising 38% over the past year.
See More
Viking Therapeutics Faces Challenges in Weight Loss Market
- Clinical Trial Progress: Viking Therapeutics' leading candidate VK2735 is undergoing pivotal 78-week phase 3 studies, with the second study recently completing enrollment; strong results could establish a solid foundation for the company in the competitive weight-loss market.
- Significant Market Potential: Analysts predict VK2735 could generate peak sales of $14.4 billion in the U.S. and $7.2 billion in Europe, totaling $21.6 billion, highlighting the drug's market potential as the weight-loss sector is projected to exceed $100 billion in the next decade.
- Increasing Competitive Pressure: While VK2735 aims to match the efficacy of Eli Lilly's Zepbound, Viking Therapeutics must demonstrate exceptional results in clinical trials to secure its position in the weight-loss drug market as competition intensifies.
- Investment Risk Advisory: Viking Therapeutics faces clinical, regulatory, competitive, and funding challenges, and while its stock may soar over the next decade, the risk of bankruptcy remains, necessitating cautious consideration from investors.
See More
Viking Therapeutics Faces Major Clinical Challenges Ahead
- Clinical Trial Progress: Viking Therapeutics' leading candidate VK2735 is undergoing two 78-week phase 3 studies, with the second recently completing enrollment; strong results could significantly enhance the company's competitive position in the rapidly growing weight-loss market.
- Massive Market Potential: Analysts predict VK2735 could generate peak sales of $14.4 billion in the U.S. and $7.2 billion in Europe, totaling $21.6 billion, and if it matches Eli Lilly's Zepbound, Viking's stock price could soar.
- Oral Drug Advantage: Viking's oral VK2735 completed phase 2 studies last year, and if it performs well in pivotal trials, it will further solidify its market position, particularly in attracting patients hesitant about injectable medications.
- Risks and Challenges: Despite the optimistic outlook, Viking Therapeutics faces clinical and regulatory risks, and increasing competition may hinder its commercial success, necessitating cautious evaluation of potential risks by investors.
See More
Wegovy Pill Shows Superior Weight Loss Over Foundayo
- Weight Loss Efficacy: The Wegovy pill demonstrated significantly greater mean weight loss of 16.6% compared to Eli Lilly's Foundayo, which showed only 12.4%, indicating Wegovy's competitive edge in the weight-loss drug market.
- Patient Preference Insights: An analysis by Novo revealed that 84% of patients preferred the drug profile of Wegovy, highlighting strong patient recognition of its lifestyle compatibility, which provides robust support for Novo's market promotion efforts.
- Market Competition Dynamics: The launch of the Wegovy pill is seen as the beginning of a new era in weight-loss medications; however, analysts note that the rapid increase in prescriptions may slow down as Foundayo approaches its market entry, potentially impacting Wegovy's market share.
- Side Effect Comparison: Recent studies indicate that Wegovy outperforms Foundayo in terms of discontinuation rates, with the latter associated with about 14 times higher odds of stopping treatment due to side effects, providing Wegovy with a crucial differentiation advantage in the increasingly competitive anti-obesity drug market.
See More
Investment Opportunities in the Healthcare Sector
- Viking Therapeutics Outlook: Viking Therapeutics has completed enrollment for its pivotal phase 3 trial of VK2735, with results expected next year, and analysts believe its stock could rise by over 60% in the coming year, with some predicting a price target exceeding $107 per share due to its leading position in obesity drug development.
- HCA Healthcare Growth Potential: HCA Healthcare operates 186 hospitals and approximately 2,400 outpatient facilities in the U.S., with same-facility admissions rising 2.4% year-over-year in Q4 2025, contributing to nearly 7% revenue growth, and management anticipates a 6% increase in annual revenue this year, driven by an aging population.
- Aging Population Drives Medical Demand: The 2020 census reported 55.8 million people aged 65 and older, accounting for 17% of the population, with projections estimating this will rise to 71.6 million by 2030, comprising 20.7% of the population, thereby increasing demand for HCA's healthcare services and strengthening its market position.
- AI Technology Enhances Operational Efficiency: HCA is leveraging its Timpani platform to improve nurse staffing through artificial intelligence, addressing bottlenecks in the U.S. healthcare system, and this forward-looking management strategy is expected to enhance service quality and operational efficiency, thereby increasing its long-term investment appeal.
See More
Investment Opportunities in Biotech and Healthcare Systems
- Biotech Potential: Viking Therapeutics has completed enrollment in a crucial phase 3 trial for its VK2735 drug, with results expected next year; analysts predict a stock price target between $107 and $125, indicating strong market potential if approved.
- Healthcare System Growth: HCA Healthcare operates 186 hospitals and 2,400 outpatient facilities in the U.S., with same-facility admissions rising 2.4% year-over-year in Q4 2025, boosting overall revenue by nearly 7% to $19.5 billion, showcasing its market advantage amid an aging population.
- Demographic Trends Impact: The 2020 census reported 55.8 million people aged 65 and older, making up 17% of the population, projected to rise to 71.6 million by 2030, comprising 20.7%, which will further drive demand for HCA's healthcare services, creating long-term growth momentum.
- AI Technology Application: HCA is leveraging its Timpani platform to improve nurse staffing through artificial intelligence, addressing bottlenecks in the U.S. healthcare system; while some market analysts are cautious about a 60% stock price increase, its long-term investment value remains significant.
See More
